HBM HLDGS LTD DL-000025
Research HBM HLDGS LTD DL-000025 (6XY) on Bullrun: market cap EUR 918.79M, P/E 10.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6XY
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 918.79M
- P/E10.0
- Financial periodFY2025
- RevenueEUR 157.98M
- Revenue growth314.6%
- Net incomeEUR 91.33M
- Free cash flowEUR 69.58M
- Gross margin94.5%
Valuation Snapshot
latest market cap is EUR 918.79M; P/E is 10.0.
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats.
Frequently asked questions
What is HBM HLDGS LTD DL-000025's market cap?
HBM HLDGS LTD DL-000025's market capitalization is EUR 918.79M.
What is HBM HLDGS LTD DL-000025's P/E ratio?
HBM HLDGS LTD DL-000025's price-to-earnings (P/E) ratio is 10.0.
What does HBM HLDGS LTD DL-000025 do?
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.